Current research of the role of Sox2 in Glioblastoma Multiforme

doi:10.11958/j.issn.0253-9896.2015.12.033

Abstract

Abstract: Glioblastoma (GBM) is one of the WHO grade Ⅳmalignancies, which is an acentral nervous system cancer with poor prognosis unless the lesion is in the brain stem. The incidence of GBM accounts for 80% of human primary malignant tumors in brain. Only 5% GBM can survive up to 5-years. Many researches showed that Sox2 is a pluripotent regulator, and muta⁃ tion or abnormal function of Sox2 are closely related to the development of GBM. There are studies demonstrated the possibil⁃ ity of using Sox2 gene as apotential target for GBM therapy. This paper reviewed recent progress in GBM.

Key words: glioblastoma, central nervous system neoplasms, gene therapy, review, Sox2

References

[1] Zhang S, Cui W. Sox2, a key factor in the regulation of pluripotency and neural differentiation[J]. World J Stem Cells. 2014,6(3):305-311.doi: 10.4252/wjsc.v6.i3.305. [2] Zhang J, Jiang H, Shao J, et al. SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis[J]. BMC Neurol. 2014,14(1):207. [Epub ahead of print] [3] Mandalos N, Rhinn M, Granchi Z, et al. Sox2 acts as a rheostat of epithelial to mesenchymal transition during neural crest development. [J]. Front Physiol. 2014, 12;5:345. doi: 10.3389/fphys.2014.00345. Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate[J]. Cell Stem Cell. 2013, 12(1): 15-30.doi: 10.1016/j.stem.2012.12.007. [4] Kamachi Y, Kondoh H.Sox proteins: regulators of cell fate specification and differentiation[J].Development,2013,140(20):4129-4144.doi: 10.1242/dev.091793. [5] Castillo SD, Sanchez-Cespedes M. The SOX family of genes in cancer development: bio?logical relevance and opportunities for thera?py[J]. Expert Opin Ther Targets. 2012, 16: 903-919. [6] de la Rocha AM, Sampron N, Alonso MM, et al. Role of SOX family of transcription factors in central nervous system tumors [J]. Am J Cancer Res. 2014 ,4(4):312-324. eCollection 2014. [7] Lee KE, Seo J, Shin J, et al. Positive feedback loop between Sox2 and Sox6 inhibits neuronal differentiation in the developing central nervous system [J]. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2794-2799. doi: 10.1073/pnas.1308758111. [8] Liu YR, Laghari ZA, Novoa CA, et al. Sox2 acts as a transcriptional repressor in neural stem cells[J].BMC Neurosci. 2014,8,15:95.doi: 10.1186/1471-2202-15-95. [9] Arnold K, Sarkar A, Yram MA, et al. Sox2(+) adult stem and progeni?tor cells are important for tissue regeneration and survival of mice[J]. Cell Stem Cell. 2011, 9: 317-329. [10] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system[J]. Acta Neuropathol. 2007, 114: 97-109. [11] Crocetti E, Trama A, Stiller C, et al. Epide?miology of glial and non-glial brain tumors in Europe[J]. Eur J Cancer. 2012, 48: 1532-1542. [12] Tanaka S, Louis DN, Curry WT, et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end[J]? Nat Rev Clin Oncol. 2013, 10: 14-26. [13] Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic land?scape of glioblastoma[J]. Cell. 2013, 155: 462-477. [14] Verhaak RG, Hoadley KA, Purdom E, et al. Integrated ge?nomic analysis identifies clinically relevant subtypes of glioblastoma characterized by ab-normalities in PDGFRA, IDH1, EGFR, and NF1[J]. Cancer Cell. 2010, 17: 98-110. [15] Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma[J]. Genes Dev. 2012, 26: 756-784. [16] Annovazzi L, Mellai M, Caldera V, et al. SOX2 expression and amplification in gliomas and glioma cell lines[J]. Cancer Ge?nomics Proteomics. 2011, 8: 139-147. [17] Schwede M, Spentzos D, Bentink S,et al. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis[J]. PLoS One. 2013,8(3):e57799. doi: 10.1371/journal.pone.0057799. [18] Holmberg J, He X, Peredo I, et al. Activation of neu?ral and pluripotent stem cell signatures corre?lates with increased malignancy in human glio?ma. PLoS One. 2011, 6: e18454. [19] Gangemi RM, Griffero F, Marubbi D, et al. SOX2 silencing in glioblasto?ma tumor-initiating cells causes stop of prolif?eration and loss of tumorigenicity[J]. Stem Cells. 2009, 27: 40-48. [20] Ikushima H, Todo T, Ino Y, et al. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein [J]. J Biol Chem. 2011,286(48):41434-41441. doi: 10.1074/jbc.M111.300863. [21] Suvà ML, Rheinbay E, Gillespie SM, et al. Reconstruct?ing and Reprogramming the Tumor-Propagat?ing Potential of Glioblastoma Stem-like Cells[J]. Cell. 2014, 157: 580-594. [22] Lalli G. Extracellular signals controlling neuroblast migration in the postnatal brain[J].Adv Exp Med Biol. 2014,800:149-180.doi: 10.1007/978-94-007-7687-6_9. [23] Oppel F, Müller N, Schackert G, et al. SOX2-RNAi at?tenuates S-phase entry and induces RhoA-de?pendent switch to protease-independent amoeboid migration in human glioma cells[J]. Mol Cancer. 2011, 10: 137. [24] Chen T, Dent SY. Chromatin modifiers and remodellers: regulators of cellular differentiation [J]. Nat Rev Genet. 2014 ,15(2):93-106. doi: 10.1038/nrg3607. [25] Alonso MM, Diez-Valle R, Manterola L, et al. Genetic and epigenetic modifications of Sox2 contribute to the inva?sive phenotype of malignant gliomas[J]. PLoS One. 2011, 6: e2674. doi: 10.1371/journal.pone.0026740. [26] Mikkelsen TS, Ku M, Jaffe DB, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells[J]. Nature. 2007, 448: 553-560. [27] Ikushima H, Todo T, Ino Y, et al. Autocrine TGF-beta sig?naling maintains tumorigenicity of glioma-initi?ating cells through Sry-related HMG-box factors[J]. Cell Stem Cell. 2009, 5: 504-514. [28] Appolloni I, Calzolari F, Tutucci E, et al. PDGF-B induc?es a homogeneous class of oligodendroglio?mas from embryonic neural progenitors[J]. Int J Cancer. 2009, 124: 2251-2259. [29] H?gerstrand D, He X, Bradic Lindh M, et al. Identifica?tion of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity pro?file[J]. Neuro Oncol. 2011, 13: 1178-1191. [30] Ge Y, Zhou F, Chen H, et al. Sox2 is trans?lationally activated by eukaryotic initiation fac?tor 4E in human glioma-initiating cells[J]. Bio?chem Biophys Res Commun. 2010, 397: 711-717. [31] Jeon HM, Sohn YW, Oh SY, et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by dere?pressing miR-9*-mediated suppression of SOX2[J]. Cancer Res. 2011, 71: 3410-3421. [32] Yang YP, Chien Y, Chiou GY, et al. Inhibition of cancer stem cell-like properties and reduced chemo?radioresistance of glioblastoma using microR?NA145 with cationic polyurethane-short bra-nch PEI[J]. Biomaterials. 2012, 33: 1462-1476. [33] P?lajeva J, Swartling FJ, Jiang Y, et al. miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma[J]. BMC Cancer. 2012, 12: 378. [34] Bier A, Giladi N, Kronfeld N, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glio?ma stem cells by targeting RTVP-1[J]. Oncotarget. 2013, 4: 665-676. [35] Fang X, Yoon JG, Li L, et al. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expres?sion microarray, and microRNA analysis[J]. BMC Genomics. 2011, 12: 11. [36] Kota J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA de?livery suppresses tumorigenesis in a murine liver cancer model[J]. Cell. 2009, 137: 1005-1017. [37] Favaro R, Valotta M, Ferri AL, et al. Hippocampal development and neural stem cell maintenance require Sox2-dependent regulation of Shh[J]. Nat Neuro?sci. 2009, 12: 1248-1256. [38] Favaro R, Appolloni I, Pellegatta S, et al. Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendro?glioma[J]. Cancer Res. 2014, 74: 1833-1844.